Improvement of pharmacokinetics and antitumor activity against human hepatoma cell line by using adriamycin-entrapped stealth liposomes

Journal of Surgical Oncology

Volumn 62, Issue 3, 1996, Pages 186-193

  Shimizu, Hiroyuki ^a   Kumai, Koichiro ^a   Uyama, Ichiro ^a   Shibata, Sansei ^a   Tagawa, Toshiaki ^b   Nagaike, Kazuhiro ^b   Yasuda, Tatsuji ^c   Kitajima, Masaki ^a   Tadakuma, Takushi ^a  

^a KEIO UNIVERSITY   (Japan)

^b Mitsubishi Chemical Ltd   (Japan)

^c OKAYAMA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

GM1; hepatoma; stealth liposomes; targeting chemotherapy

Indexed keywords

DOXORUBICIN; DRUG CARRIER; LIPOSOME;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; LIPOSOMES; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; TIME FACTORS; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 0029979842     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199607)62:3<186::AID-JSO8>3.0.CO;2-3     Document Type: Article

References (30)

1. Weinstein JN: Liposomes as drug carriers in cancer therapy. Cancer Treat Rep 68:127-135, 1984.
2. Tadakuma T: Targeting therapy of human solid tumor cells with liposomes bearing monoclonal antibodies. In Yagi K (ed): "Medical Application of Liposomes." Tokyo: Japan Scientific Societies Press, and S Karger AG, 1985, p 113-119.
3. Konno H, Suzuki H, Tadakuma T, et al.: Antitumor effect of adriamycin entrapped in liposomes conjugated with anti-human alpha-fetoprotein monoclonal antibody. Cancer Res 47:4471-4477, 1987.
4. Fidler IJ, Raz A, Fogler WE, et al.: Design of liposomes to improve delivery of macrophage-augmenting agents to alveolar macrophages. Cancer Res 40:4460-4466, 1980.
5. Barbet J, Machy P, Leserman LD: Monoclonal antibody covalently coupled to liposomes: Specific targeting to cells. J Suprastruct Cell Biochem 16:243-258, 1981.
6. Hosokawa S, Muramatsu M, Nagaike K: Detection of membrane-bound alpha-fetoprotein in human hepatoma cell lines by monoclonal antibody 19F12. Cancer Res 49:361-366, 1989.
7. Geran RI, Greenberg NH, MacDonald MM, et al.: Protocols and natural products against animal tumors and other biological system (Third Edition). Cancer Chemother Rep 3:51-85, 1972.
8. Poste G, Bucana C, Raz, A, et al.: Analysis of the fate of systemi-cally administered liposomes and implications for their use in drug delivery. Cancer Res 42:1412-1422, 1982.
9. Hashimoto Y, Sugawara M, Masuko T, Hojo H: Antitumor effect of actinomycin D entrapped in liposomes bearing subunits of tumor specific monoclonal immunoglobulin M antibody. Cancer Res 43: 5328-5334, 1983.
10. Allen TM, Smuckler EA: Liver pathology accompanying chronic liposome administration in mouse. Res Commun Chem Pathol Pharmacol 50:281-290, 1985.
11. Yamakawa T, Nagai Y: Glycolipids at the cell surface and their biological functions. Trends Biochem 3:128-131, 1978.
12. Hakomori S: Glycosphingolipids in cellular interaction, differentiation, and oncogenesis. Annu Rev Biochem 50:733-764, 1983.
13. Allen TM, Chonn A: Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett 223:42-46, 1987.
14. Papahadjopoulos D, Gabizon A: Targeting of liposomes to tumor cells in vivo. Ann NY Acad Sci 507:64-71, 1987.
15. Gabizon A, Papahadjopoulos D: Liposome formulation with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 85:6949-6953, 1988.
16. Gabizon A, Papahadjopoulos D: The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim Biophys Acta 1103:94-100, 1992.
17. Allen TM, Hansen C, Rutledge J: Liposomes with prolonged circulation times: Factors affecting uptake by reticuloendothelial and other tissues. Biochim Biophys Acta 981:27-35, 1989.
18. Mori A, Klivanov AL, Torchilin VP, Huang L: Influence of the steric barrier activity amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo. FEBS Lett 284:263-266, 1991.
19. Maruyama K, Kennel SJ, Huang L: Lipid composition is important for highly efficient targeting binding and retention of immunolipo-somes. Proc Natl Acad Sci USA 87:5744-5748, 1990.
20. Wu NZ, Da D, Rudoll TL, et al.: Increased microvascular permeability contributes to preferential accumulation of stealth liposomes in tumor tissue. Cancer Res 53:3765-3770, 1993.
21. Gabizon A, Price DC, Huberty J, et al.: Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: Biodistribution and imaging studies. Cancer Res 50:6371-6378, 1990.
22. Gabizon A: Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res 52:891-896, 1992.
23. Allen TM, Hansen C, Martin F, et al.: Liposomes containing synthetic lipid derivatives of poly(ethyleneglycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1066:29-36, 1991.
24. Mayhew EG, Lasic DD, Babbar S, Martin FJ: Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethyleneglycol-derivatized phospholipid. Int J Cancer 51:302-309, 1992.
25. Ahmad I, Longenecker M, Samuel J, Allen TM: Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. Cancer Res 53:1484-1488, 1993.
26. Klivanov AL, Maruyama K, Torchilin VP, Huang L: Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 268:235-237, 1990.
27. Oku N, Namba Y, Okada S: Tumor accumulation of novel RES-avoiding liposomes. Biochim Biophys Acta 1126:255-260, 1992.
28. Courtenary-Luck NS, Epenetos AA, Moore R, et al.: Development of primary secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res 46:6489-6493, 1986.
29. LoBuglio AF, Wheeler RH, Trang J, et al.: Mouse/human chimeric monoclonal antibody in man: Kinetic and immune response. Proc Natl Acad Sci USA 86:4220-4224, 1989.
30. Uyama I, Kumai K, Yasuda T, et al.: Improvement of therapeutic effect by using Fab' fragment in the treatment of carcinoembryonic antigen-positive human solid tumor with Adriamycin-entrapped immunoliposomes. Jpn J Cancer Res 85:434-440, 1994.